Skip to Content

News & Events

Press Releases

Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov 9, 2005	Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Cambridge, MA, November 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday, November 11, 2005 at 9:00 a.m. EST. Webcasts	View HTML Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting 7.8 KB
Toggle SummaryNov 11, 2005	AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor Vertex Announces Filing of IND in Support of VX-950 Phase II Development in the U.S. HCV	View HTML AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor 23.9 KB
Toggle SummaryNov 18, 2005	FDA Approves Updated Labeling for LEXIVA - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA - General Business	View HTML FDA Approves Updated Labeling for LEXIVA 15.1 KB
Toggle SummaryNov 18, 2005	FDA Approves Updated Labeling for LEXIVA - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA - General Business	View HTML FDA Approves Updated Labeling for LEXIVA 15.1 KB
Toggle SummaryDec 5, 2005	Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 - Investigational New Drug Application Activated in the U.S. - General Business	View HTML Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 12.9 KB
Toggle SummaryDec 5, 2005	Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 - Investigational New Drug Application Activated in the U.S. - HCV	View HTML Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 12.9 KB
Toggle SummaryDec 7, 2005	Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study - Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors - General Business	View HTML Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study 12.4 KB
Toggle SummaryDec 7, 2005	Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study - Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors - Other	View HTML Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study 12.4 KB
Toggle SummaryDec 8, 2005	FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 FDA Grants Fast Track Designation to Vertex’s Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to General Business	View HTML FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 12 KB
Toggle SummaryDec 8, 2005	FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HCV	View HTML FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 12 KB